LISTING OF CLAIMS

1-8. (Canceled).

9. (Previously presented) A pharmaceutical composition for administration to a subject mammal exhibiting a diurnal cycle of plasma aldosterone concentration having an acrophase, the composition comprising a therapeutically effective amount of a delayed-release formulation of an aldosterone antagonist drug which, when orally administered about 6 to about 12 hours prior to the acrophase, provides a profile of plasma drug concentration corresponding to the diurnal cycle of plasma aldosterone concentration, wherein the composition further comprises a second formulation comprising a therapeutically effective amount of a second antihypertensive agent.

b1

10. (Original) The composition of Claim 9 wherein said second antihypertensive agent is selected from a diuretic, a sympatholytic agent, an ACE inhibitor, a vasopeptidase, a calcium channel blocker, a direct vasodilator, a renin inhibitor, and an angiotensin II antagonist.

11. (Original) The composition of Claim 9 wherein the second formulation containing the second antihypertensive agent exhibits

a release profile that is different from the release profile exhibited by the delayed-release formulation containing the aldosterone antagonist.

12. (Original) The composition of Claim 11 wherein the second formulation is an immediate-release formulation.

13. (Original) The composition of Claim 11 wherein the second formulation is an extended-release formulation.

14-22. (Canceled).

b1

23. (New) A pharmaceutical composition for administration to a subject mammal exhibiting a diurnal cycle of plasma aldosterone concentration having an acrophase, the composition comprising a therapeutically effective amount of a delayed-release formulation of an aldosterone antagonist drug which, when orally administered about 6 to about 12 hours prior to the acrophase, provides a profile of plasma drug concentration corresponding to the diurnal cycle of plasma aldosterone concentration, wherein the aldosterone antagonist drug is selected from the group consisting of eplerenone and spironolactone, and wherein the composition further comprises a second formulation comprising a

therapeutically effective amount of a second antihypertensive agent.

24. (New) The composition of Claim 23 wherein said second antihypertensive agent is selected from a diuretic, a sympatholytic agent, an ACE inhibitor, a vasopeptidase, a calcium channel blocker, a direct vasodilator, a renin inhibitor, and an angiotensin II antagonist.

25. (New) The composition of Claim 23 wherein the second formulation containing the second antihypertensive agent exhibits a release profile that is different from the release profile exhibited by the delayed-release formulation containing the aldosterone antagonist.

26. (New) The composition of Claim 25 wherein the second formulation is an immediate-release formulation.

27. (New) The composition of Claim 25 wherein the second formulation is an extended-release formulation.